Azimuth Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Azimuth Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$9.13M	Buy	34,984 +1,409	+4%	+$334K	0.39%	91
2021 Q4	$7.37M	Sell	33,575 -194	-0.6%	-$37.7K	0.3%	120
2021 Q3	$6.13M	Sell	33,769 -1,382	-4%	-$270K	0.26%	130
2021 Q2	$7.09M	Sell	35,151 -1,500	-4%	-$314K	0.31%	118
2021 Q1	$7.88M	Sell	36,651 -15,109	-29%	-$3.32M	0.37%	100
2020 Q4	$12.2M	Buy	51,760 +822	+2%	+$189K	0.61%	57
2020 Q3	$13.9M	Sell	50,938 -11,155	-18%	-$3.08M	0.82%	39
2020 Q2	$18M	Sell	62,093 -14,491	-19%	-$3.93M	1.15%	14
2020 Q1	$18.2M	Sell	76,584 -558	-0.7%	-$128K	1.37%	7
2019 Q4	$16.9M	Buy	77,142 +24,427	+46%	+$4.94M	1.03%	20
2019 Q3	$8.93M	Buy	52,715 +2,607	+5%	+$461K	0.58%	67
2019 Q2	$9.19M	Buy	50,108 +646	+1%	+$113K	0.61%	60
2019 Q1	$9.1M	Buy	49,462 +1,035	+2%	+$191K	0.61%	62
2018 Q4	$8.03M	Sell	48,427 -8,600	-15%	-$1.49M	0.61%	57
2018 Q3	$11M	Sell	57,027 -45	-0.1%	-$8.01K	0.74%	41
2018 Q2	$9.7M	Buy	57,072 +28,235	+98%	+$4.38M	0.7%	48
2018 Q1	$4.7M	Buy	+28,837	New	+$4.71M	0.35%	108

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Azimuth Capital Management's VRTX Position: Q1 2022 in Review

Azimuth Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 4.2% in Q1 2022, buying an estimated $334K and bringing the position to 34,984 shares worth $9.13M. The position accounts for 0.39% of the portfolio, ranked #91.

Azimuth Capital Management first reported a position in VRTX in Q1 2018 and has held it in 17 quarters since. The position peaked at $18.2M in Q1 2020. 1,071 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

Azimuth Capital Management held 34,984 shares of Vertex Pharmaceuticals worth $9.13M as of Q1 2022.
Azimuth Capital Management bought 1,409 Vertex Pharmaceuticals shares in Q1 2022, an estimated $334K.
Vertex Pharmaceuticals made up 0.39% of Azimuth Capital Management's portfolio in Q1 2022, its #91 holding.
Azimuth Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 17 quarters since.
Azimuth Capital Management's Vertex Pharmaceuticals position peaked at $18.2M in Q1 2020.
1,071 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Azimuth Capital Management's 13F filing for Q1 2022, filed 13 May 2022.